List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated targets. Matthew Lloyd from the University of Bath explains why these hits can arise during drug discovery and how machine learning could be the answer to identifying these compounds.
While researchers conduct their studies, constraints such as time can impact their work. Dr Ian Holland from the University of Edinburgh spoke with Drug Target Review’s Deputy Editor Victoria Rees to explain how lab automation can offer a solution to these challenges and enhance output for scientists.
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
Researchers have developed a native state mass spectrometry technique to identify inhibitors of the bacterial protein metallo-beta-lactamase.
A National Science and Technology Council and Office for Science and Technology Strategy will be established to aid the UK's scientific industry.
This ebook has articles on the use of screening to identify COVID-19 drugs and how assessing compound activity could accelerate drug discovery.
A new radiopharmaceutical compound has shown success at treating ovarian cancer in mice and in vitro studies.
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
